secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001140361-25-024089
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M
--------------------------------------------------------------------------------

- Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.
- Transaction expected to close in October 2025, subject to antitrust clearance and customary closing conditions.
- BioCryst will continue as exclusive supplier of ORLADEYO under a supply agreement and enter IP license, brand support, and transition services agreements.
- Sale includes all equity of BioCryst Ireland Limited, which holds European ORLADEYO assets and rights.
- The amended IP license may extend to the pediatric line extension of ORLADEYO subject to regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000114036125024089/0001140361-25-024089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000114036125024089/ef20051351_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-024089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer